Medtronic plc (MDT) Options Risk Score
Real-time risk analysis for MDT options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full MDT options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan MDT Now — Free →
Is it risky to sell options on Medtronic plc (MDT) right now?
Medtronic plc (MDT) currently scores 51 out of 100 for options catalyst risk (MEDIUM) over a 4-week expiry window. What pushes it there: an upcoming earnings report, 8 recent news items, 6 active legal filings and 28 clinical-trial catalysts, all landing inside the 4-week window. A mid-range score (45–69) means MDT is neither clear nor obviously dangerous over this window — check which specific date is driving it before choosing a strike. The number reflects event exposure only.
MDT shows an IV Rank of 90 — implied volatility is near the top of its own one-year range, so MDT options are historically expensive, which favours premium-selling strategies, with a current implied volatility of about 34%. IV Rank is the most useful figure for deciding whether to sell or buy premium on MDT.
The 2026-09-01 earnings report sits inside a standard monthly expiry for MDT, so implied volatility should stay bid into the date and drop sharply once it passes.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer